GSK’s Ris-Rez Meets Primary Endpoint In Phase III ARTEMIS-011 Trial, Reducing Risk Of Progression Or Death By 67%, Improving Median Progression-Free Survival To 5.5 Months Vs. 1.4 Months With Chemotherapy In Relapsed Or Refractory Osteosarcoma

뉴스 본문을 불러오고 있어요.

GSK’s Ris-Rez Meets Primary Endpoint In Phase III ARTEMIS-011 Trial, Reducing Risk Of Progression Or Death By 67%, Improving Median Progression-Free Survival To 5.5 Months Vs. 1.4 Months With Chemotherapy In Relapsed Or Refractory Osteosarcoma | 웨이프 WAPE

GSK’s Ris-Rez Meets Primary Endpoint In Phase III ARTEMIS-011 Trial, Reducing Risk Of Progression Or Death By 67%, Improving Median Progression-Free Survival To 5.5 Months Vs. 1.4 Months With Chemotherapy In Relapsed Or Refractory Osteosarcoma

기사 요약

관련 종목

댓글 —